Inhibitor Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Inhibitor Therapeutics, Inc. (INTI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.06 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-26
- Inhibitor Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $0.06, a 25.00% decline from fiscal 2024.
- Inhibitor Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $0.08.
- Inhibitor Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $0.09, a 10.00% decline from fiscal 2021.
- Inhibitor Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $0.10, a 0.00% change from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $0.06 10-K · filed 2026-03-26 |
| 2024-12-31 | $0.08 10-K · filed 2026-03-26 |
| 2022-12-31 | $0.09 10-K · filed 2023-03-31 |
| 2021-12-31 | $0.10 10-K · filed 2023-03-31 |
| 2020-12-31 | $0.10 10-K · filed 2023-03-31 |
| 2014-12-31 | $0.00 10-K · filed 2015-02-13 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-13 |